Let me tell you something that most people outside of medical sales circles don’t get — just because a medicine is effective, affordable, and already popular doesn’t mean it’ll show up in a government hospital near you. Nope. Not in Malaysia. Because first, that product needs to masuk buku.
And I’m talking about the Blue Book.
Now if you’re imagining some mysterious leather-bound manual sitting in a locked drawer in Putrajaya, it’s not that dramatic lah. But to us in the industry, this Blue Book is everything when it comes to supplying our meds to MOH hospitals.
See, without being listed in this official formulary, even the most amazing generic drug — let’s say a solid painkiller, or a reliable anti-ulcer agent — is practically invisible to the people working in these hospitals. Doctors can’t prescribe it, pharmacists can’t stock it, procurement officers won’t touch it. It’s like your product never existed.
You can win over a thousand private doctors, have a thousand testimonies... but without the Blue Book stamp?
Sorry boss, not here.
And oh, getting into the Blue Book isn’t a walk in the park either. It's not a matter of just filling in a form and waiting. There’s an entire process involving clinical evidence, registration with NPRA, pricing negotiations, comparisons with existing formulary drugs, therapeutic need, and a bunch of other considerations. Your product could be better than the current one on the list — cheaper, safer, whatever — but if there's no perceived gap or urgency, it can get stuck in limbo.
What does that mean for us reps?
Well, if we’re handling a product not in the Blue Book, our job just got ten times harder. You walk into a GH pharmacy and try to talk about your product — they shut it down immediately. “Tak dalam Blue Book kan? Sorry, kita tak boleh consider.” End of conversation.
And you just burned petrol and drove 3 hours from Bentong for that one shot.
Even more heartbreaking? Sometimes you know your product could help. Say there’s a shortage of an APPL item — and your product is in stock, approved by NPRA, and used widely in private sector. But because it’s not in that magical Blue Book, it’s untouchable.
Frustrating?
You have no idea.
And here's the kicker — some of these Blue Book-listed items haven’t changed in years. While the rest of the pharma world moves on, newer generics and formulations are kept outside the fence because the system is, well… a little slow to adapt. It’s like trying to stream Netflix with a dial-up modem. The intention is there, but the system’s not always ready for change.
Of course, if your product does get into the Blue Book, congrats!
But the journey doesn't stop there. It still has to go through APPL inclusion, tender processes, pricing ceilings, and so on. And let’s be real — by the time all of that is done, your excitement dah sejuk.
Welcome to the long game.
But here’s the thing that outsiders really don’t see:
This Blue Book system, though slow and rigid at times, exists for a reason. It’s about maintaining consistency, fairness, and cost-effectiveness across hundreds of facilities. The intention is noble. But for reps like us, it’s a daily test of patience and creativity.
We’re out there navigating these roadblocks, explaining to new teammates why a fantastic product can’t even get a mention at the state hospital, and why the best sales pitch in the world won't matter if you don't have the right paperwork.
So next time someone asks why they don’t see your product in GHs, just smile and say, “Belum masuk buku lagi, boss.”
Because deep down, you know that sentence holds a world of red tape, strategy, frustration, and maybe — just maybe — a glimmer of hope.
Disclaimer:
This post is based on personal experiences and general
practices within the Malaysian pharmaceutical industry. It does not represent
the official stance of any agency or institution. For up-to-date and accurate
guidelines, always refer to the Ministry of Health (MOH) or relevant regulatory
bodies.
No comments:
Post a Comment